Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

CBMG / Cellular Biomedicine Group, Inc. / Sailing Capital Overseas Investments Fund, Lp - SC 13D (Activist Investment)

2018-02-16 sec.gov
SC 13D     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.     )*     Cellular Biomedicine Group, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 15117P102 (CUSIP Number) Sailing Capital Overseas Investments Fund, L.P. Unit 2006-08 20/F Harbour Centre, 25 Harbour Road Wan Chai, Hong Kong With a copy to: Daniel R.

CBMG / Cellular Biomedicine Group, Inc. / Sailing Capital Overseas Investments Fund, Lp - SC 13D (Activist Investment)

2018-02-15 sec.gov
SC 13D     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.     )*     Cellular Biomedicine Group, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 15117P102 (CUSIP Number) Sailing Capital Overseas Investments Fund, L.P. Unit 2006-08 20/F Harbour Centre, 25 Harbour Road Wan Chai, Hong Kong With a copy to: Daniel R.

CBMG / Cellular Biomedicine Group, Inc. CURRENT REPORT (Current Report)

2018-02-15 sec.gov
Blueprint   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): February 15, 2018   CELLULAR BIOMEDICINE GROUP, INC. (Exact name of registrant as specified in its charter)   Delaware   001-36498   86-1032927 (State or other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.

CBMG / Cellular Biomedicine Group, Inc. CURRENT REPORT (Current Report)

2018-02-12 sec.gov
Blueprint     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): February 6, 2018   CELLULAR BIOMEDICINE GROUP, INC. (Exact name of registrant as specified in its charter)   Delaware   001-36498   86-1032927 (State or other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.

Week In Review: Tsinghua University Invests $276 Million In Cambridge U.K. Biohub

2018-02-11 seekingalpha
Tsinghua University Holdings (TUS) of Beijing will invest $276 million to build a new biohub in the UK's Cambridge Science Park. The biohub will be a joint venture between TUS and Trinity College, Cambridge, the owner of the park. The money will build five new buildings, comprising 350,000 square feet. This includes a state-of-the-art biohub, which will provide labs and offices for early stage companies working on a wide range of healthcare technologies, including non-invasive diagnostics, new drugs, novel surgical techniques, and new home-monitoring technologies. (80-1)

CBMG / Cellular Biomedicine Group, Inc. PRESS RELEASE, DATED FEBRUARY 5, 2018

2018-02-07 sec.gov
Blueprint   Exhibit 99.1 Cellular Biomedicine Group Announces $30.6 million Investment from Sailing Capital Overseas Investment Ltd.   SHANGHAI, China and CUPERTINO, Calif., February 5, 2018 /GlobeNewswire/ -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a biopharmaceutical firm engaged in the development of immunotherapies for cancer, today announced the receipt of a $30.

CBMG / Cellular Biomedicine Group, Inc. AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT

2018-02-07 sec.gov
Blueprint   Exhibit 10.1   AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT   This Amendment No. 1 dated as of February 5, 2018 (this “Amendment”) by and between Cellular Biomedicine Group, Inc., a Delaware corporation (the “Company”) and Wealth Map Holdings Limited, Earls Mill Limited, Bosun S. Hau and Rui Zhang (each, a “Purchaser” and together, the “Purchasers”), amends that certain Securities Purchase Agreement dated as of January 30, 2018 between the Company and the Purchasers (the “Securit

CBMG / Cellular Biomedicine Group, Inc. AMENDMENT NO. 1 TO REGISTRATION RIGHTS AGREEMENT

2018-02-07 sec.gov
Blueprint   Exhibit 4.1   AMENDMENT NO. 1 TO REGISTRATION PURCHASE AGREEMENT   This Amendment No. 1 dated as of February 5, 2018 (this “Amendment”) by and between Cellular Biomedicine Group, Inc., a Delaware corporation (the “Company”) and Wealth Map Holdings Limited, Earls Mill Limited, and Bosun S. Hau (each an “Investor” and together the “Investors”) amends that certain Registration Rights Agreement dated as of January 30, 2018 between the Company and the Investors (the “Registration Rights A

CBMG / Cellular Biomedicine Group, Inc. CURRENT REPORT (Current Report)

2018-02-07 sec.gov
Blueprint   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): February 5, 2018   CELLULAR BIOMEDICINE GROUP, INC. (Exact name of registrant as specified in its charter)   Delaware   001-36498   86-1032927 (State or other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.

CBMG / Cellular Biomedicine Group, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-02-02 fintel.io
Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) has 20 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 1,629,090 shares. Largest shareholders include Maplebrook Ltd, Millennium Management Llc, BlackRock Inc., Vanguard Group Inc, Bridgeway Capital Management Inc, Geode Capital Management, Llc, Northern Trust Corp, Element Capital Management Llc, California Public Employees Retirement System, and Dimensional Fund Advisors Lp. (35-0)

CBMG / Cellular Biomedicine Group, Inc. / Maplebrook Ltd - SC 13G (Passive Investment)

2018-02-02 sec.gov
Blueprint   SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 13G (Amendment No. )   Under the Securities Exchange Act of 1934     Cellular Biomedicine Group, Inc.     (Name of Issuer)           Common Stock, $0.001 par value per share     (Title of Class of Securities)           15117P102     (CUSIP Number)           December 28, 2017     (Date of Event Which Requires Filing of this Statement)         Check the appropriate box to designate the rule pursuant to which this Sche

CBMG / Cellular Biomedicine Group, Inc. / Maplebrook Ltd - SC 13G (Passive Investment)

2018-02-02 sec.gov
Blueprint   SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 13G (Amendment No. )   Under the Securities Exchange Act of 1934     Cellular Biomedicine Group, Inc.     (Name of Issuer)           Common Stock, $0.001 par value per share     (Title of Class of Securities)           15117P102     (CUSIP Number)           December 28, 2017     (Date of Event Which Requires Filing of this Statement)         Check the appropriate box to designate the rule pursuant to which this Sche

CBMG / Cellular Biomedicine Group, Inc. SECURITIES PURCHASE AGREEMENT

2018-01-31 sec.gov
Blueprint   Exhibit 10.1     SECURITIES PURCHASE AGREEMENT   BY AND AMONG   CELLULAR BIOMEDICINE GROUP, INC.,   WEALTH MAP HOLDINGS LIMITED,   EARLS MILL LIMITED, AND   BOSUN S. HAU   JANUARY 30, 2018           TABLE OF CONTENTS     1 Definitions 1 2 Authorization, Purchase and Sale of Common Stock 5 2.1 Authorization, Purchase and Sale 5 2.2 Closing 5 3 Representations and Warranties of the Company 5 3.

CBMG / Cellular Biomedicine Group, Inc. REGISTRATION RIGHTS AGREEMENT

2018-01-31 sec.gov
Blueprint   Exhibit 4.1       REGISTRATION RIGHTS AGREEMENT   This Registration Rights Agreement (this “Agreement”) is made and entered into as of January 30, 2018, by and among Cellular Biomedicine Group, Inc., a Delaware corporation (the “Company”), Wealth Map Holdings Limited, Earls Mill Limited, and Bosun S. Hau (each an “Investor” and together the “Investors”).   WHEREAS, the Investors have, pursuant to that certain Securities Purchase Agreement, dated as of January 30, 2018, between the Co

CBMG / Cellular Biomedicine Group, Inc. CURENT REPORT (Current Report)

2018-01-31 sec.gov
Blueprint   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): January 30, 2018   CELLULAR BIOMEDICINE GROUP, INC. (Exact name of registrant as specified in its charter)   Delaware   001-36498   86-1032927 (State or other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.


CUSIP: 15117P102